SCHEMBL17824799

SCHEMBL17824799

O=S(=O)(Cl)c1ccc2ccnc(Cl)c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 1/20 0.58
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
APEX1 P27695 1/20 0.46
MAPK1 P28482 1/20 0.46
PMP22 Q01453 1/20 0.46
PLG P00747 2/20 0.43
PLAU P00749 2/20 0.43
PLAT P00750 2/20 0.43
HIPK2 Q9H2X6 2/20 0.39
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HTR6 P50406 2/20 0.35
HTR1A P08908 1/20 0.35
HTR2A P28223 1/20 0.35
HTR7 P34969 1/20 0.35
NFE2L2 Q16236 2/20 0.32
CYP2A6 P11509 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15010065 0.86 PARG (0.45) PARGLMNACYP3A4MAPTAPEX1
SCHEMBL6993419 0.85 PLAU (0.60) PARGLMNACYP3A4MAPTAPEX1
SCHEMBL27527771 0.81 PARG (0.53) PARGLMNACYP3A4MAPTAPEX1
SCHEMBL6998566 0.76 PLG (0.65) PARGMAPTMAPK1PLGPLAU
Propylene Oxide SCHEMBL11889807 0.74 PARG (0.53) PARGLMNACYP3A4MAPTAPEX1
SCHEMBL17825169 0.74 PARG (1.00) PARG
SCHEMBL1317870 0.74 LMNA (0.50) PARGLMNACYP3A4MAPTAPEX1
SCHEMBL29786977 0.74 LMNA (0.50) PARGLMNACYP3A4MAPTAPEX1
SCHEMBL6433525 0.72 PLAU (0.48) PLGPLAUPLATALDH1A1HSD17B10
SCHEMBL2589369 0.72 DYRK1B (0.40) MAPTMAPK1ALDH1A1HSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-03-26 US disclosed
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-01-18 US disclosed
EP-3230273-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG Cancer Research Technology Ltd (GB) 2017-10-18 EP disclosed
CN-107207467-A 2, 4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG 癌症研究科技有限公司 2017-09-26 CN disclosed
WO-2016092326-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-16 WO disclosed
CN-1318059-A Isoquinolines as urokinase inhibitors PFIZER (US) 2001-10-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG PARG, PARP15, PARP12 PARG 1/4885LMNA 499/4885CYP3A4 753/4885
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG PARG, PARP15, PARP12 PARG 1/4885LMNA 499/4885CYP3A4 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.